Preclinical studies show BPC-157 promotes rotator cuff tendon healing in animal models. Supraspinatus and infraspinatus recovery with total functional restoration. Here's the data breakdown.
Rotator cuff injuries are among the most common musculoskeletal complaints. Over 2 million Americans visit doctors for rotator cuff problems annually. Current treatments often fail to restore full function — surgical repair failure rates can reach 20-70%.
Body Protection Compound-157 is a 15-amino-acid peptide derived from human gastric juice. First described in 1992, it's been studied for tissue healing across multiple organ systems — with over 544 articles published to date.
In 2014, researchers published a preclinical study on BPC-157's effects on surgically-induced rotator cuff tears in rats. The results showed remarkable recovery in treated animals.
Study design: Animal model (rat). Surgically-created rotator cuff tears involving supraspinatus and infraspinatus tendons. BPC-157 administered vs control. Outcomes measured: functional recovery, tendon healing, mobility, muscle strength.
"In animals treated with pentadecapeptide BPC 157 was observed total functional recovery similar to healthy animals, along with supraspinate and infraspinate tendon healing."
Sikiric et al. Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat. FASEB Journal 2014
A 2011 study revealed the specific mechanisms by which BPC-157 accelerates tendon repair. These findings help explain the rotator cuff results.
Chang CH, Tsai WC, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011 Mar;110(3):774-80.
PMID: 21030672 • View on PubMed →
A comprehensive 2025 systematic review (PMC12313605) synthesized 36 studies on BPC-157's musculoskeletal effects. Here's what the literature shows about how it works.
Why this matters for shoulders: Rotator cuff tendons have notoriously poor blood supply — the "critical zone" of the supraspinatus is especially vulnerable. BPC-157's ability to promote angiogenesis may address this fundamental healing limitation. Combined with enhanced fibroblast activity and reduced inflammation, these mechanisms target the key obstacles to rotator cuff recovery.
While no human shoulder studies exist, the knee pain study (PMID: 34324435) provides insight into how BPC-157 performs for joint and tendon conditions in humans. The mechanisms are applicable to shoulder structures.
Extrapolation caveat: The following data is from knee joint injections, not shoulders. While the underlying mechanisms are similar (tendons, ligaments, cartilage), direct shoulder efficacy has not been tested in humans. Interpret cautiously.
| Factor | Knee Study Result | Potential Shoulder Application |
|---|---|---|
| Conditions Treated | Osteoarthritis, meniscus tears, ligament sprains | Rotator cuff tears, tendinitis, impingement (hypothetical) |
| Administration Route | Intra-articular injection | Glenohumeral joint or peri-tendon injection |
| Number of Injections | Single injection | Likely similar (based on mechanism) |
| Adverse Events | 0 of 12 (0%) | Unknown for shoulder administration |
| Relief Duration | 6-12 months | Potentially similar (tendon mechanism shared) |
| Evidence Level | Small pilot study (n=12), no placebo | No direct shoulder evidence |
Intra-articular BPC-157 injection for knee pain from osteoarthritis, meniscus tears, and ligament sprains.
PMID: 34324435 • View on PubMed →
How does BPC-157's theoretical mechanism compare to established shoulder pain treatments? Based on preclinical data and the knee study methodology.
| Factor | Cortisone | PRP | Physical Therapy | BPC-157 (Theoretical) |
|---|---|---|---|---|
| Mechanism | Suppresses inflammation | Growth factors from platelets | Strengthen surrounding muscles | Tissue repair + angiogenesis |
| Duration of Relief | 2-6 weeks | 3-6 months (variable) | Long-term if maintained | 6-12 months (knee data) |
| Effect on Tissue | Degrades tendon | May promote healing | No direct tissue effect | Promotes repair (preclinical) |
| Repeat Injections | Max 3-4/year | 1-3 treatments | Ongoing sessions | Single (knee data) |
| Cost | $50-150 | $500-2,000 | $100-250/session | Variable (unregulated) |
| FDA Status | FDA-approved | FDA-cleared devices | Standard of care | Not approved |
| Evidence Level | Decades of RCTs | Mixed, moderate | Strong for function | Preclinical only |
The 2025 systematic review found no adverse effects in preclinical studies. However, clinical safety data remains extremely limited.
Critical limitation: While preclinical safety data is reassuring, no published human clinical safety studies exist. Products sold as "BPC-157" are unregulated — contamination, incorrect dosing, and impurities are possible. The FDA classified BPC-157 as Category 2 in 2023, meaning it "raises significant safety concerns" due to insufficient human evidence.
Essential supplies for peptide reconstitution and injection protocols.
Affiliate links help support HighPeptides at no extra cost to you.
Third-party tested peptides with certificates of analysis. Used by researchers worldwide.
Browse BPC-157 at Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
In a preclinical animal study (Sikiric 2014), rats with surgically-induced rotator cuff tears showed "total functional recovery similar to healthy animals" when treated with BPC-157. The supraspinatus and infraspinatus tendons showed complete healing. However, no human clinical trials have been conducted specifically for rotator cuff injuries — the animal results have not been validated in humans.
According to published research (PMID: 21030672), BPC-157 promotes tendon healing through multiple mechanisms: accelerating tendon fibroblast outgrowth from explants, increasing cell survival under oxidative stress, and promoting cell migration via activation of the FAK-paxillin pathway. It also upregulates growth hormone receptor expression in tendon fibroblasts and promotes angiogenesis (new blood vessel formation).
No. There are no published human clinical trials specifically for shoulder pain or rotator cuff injuries. The only relevant human data comes from a knee study (PMID: 34324435) showing 11 of 12 patients reported pain relief lasting 6-12 months for conditions including ligament and tendon injuries. The mechanism may be applicable to shoulder tendons, but this has not been tested.
Based on the knee study methodology, BPC-157 would likely be administered via intra-articular injection (directly into the glenohumeral joint space) or subcutaneous injection near the injured tendon. The rotator cuff animal study used intraperitoneal injection. Route selection should be guided by a qualified medical professional. Self-administration is not recommended.
No. BPC-157 is not FDA-approved for any medical condition. In 2023, the FDA classified it as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies and "raises significant safety concerns" due to insufficient human evidence. It remains a research peptide with no approved clinical indications.
⚕️ Medical Disclaimer
This page is for educational and informational purposes only. It is not medical advice. BPC-157 is not FDA-approved for any medical condition. The studies cited are preliminary — animal models and small human studies without placebo controls. No human clinical trials exist for shoulder-specific conditions. Always consult a qualified healthcare professional before making decisions about any peptide, supplement, or treatment protocol. Do not use this information to self-diagnose or self-treat any condition.
This page contains affiliate links. HighPeptides may earn a commission at no additional cost to you.